<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182257</url>
  </required_header>
  <id_info>
    <org_study_id>ONO-7579-01</org_study_id>
    <nct_id>NCT03182257</nct_id>
  </id_info>
  <brief_title>Study of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors</brief_title>
  <acronym>ONTRK</acronym>
  <official_title>An Open-label, Multi-center, Dose-escalation and Expansion Study to Evaluate the Safety and Efficacy of ONO-7579 in Patients With Advanced Solid Tumors/ NTRK Gene Fusion Positive Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ono Pharmaceutical Co. Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety and maximum tolerated dose of ONO-7579 in patients with&#xD;
      advanced solid tumors, and evaluate efficacy of ONO-7579 in patients with advanced solid&#xD;
      tumors harboring NTRK gene fusions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial was designed to be a Phase 1/2 trial, but was terminated without progressing to&#xD;
      Phase 2.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was stopped for commercial reasons. No safety issues were reported.&#xD;
  </why_stopped>
  <start_date type="Actual">July 12, 2017</start_date>
  <completion_date type="Actual">January 30, 2018</completion_date>
  <primary_completion_date type="Actual">January 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Incidence, nature and severity of Adverse Events</measure>
    <time_frame>up to 28 days</time_frame>
    <description>To investigate the safety and tolerability of ONO-7579 to determine MTD/RCD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Clinically significant changes in physical examinations</measure>
    <time_frame>up to 28 days</time_frame>
    <description>To investigate the safety and tolerability of ONO-7579 to determine MTD/RCD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Clinically significant changes in neurological examinations</measure>
    <time_frame>up to 28 days</time_frame>
    <description>To investigate the safety and tolerability of ONO-7579 to determine MTD/RCD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Clinically significant changes in vital signs and electrocardiogram - including the evaluation of the QT interval</measure>
    <time_frame>up to 28 days</time_frame>
    <description>To investigate the safety and tolerability of ONO-7579 to determine MTD/RCD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Overall Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessed by Independent Central Review using RECIST 1.1 or RANO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A and B Pharmacokinetics (Cmax)</measure>
    <time_frame>Day 1, 2, 7, 14 and 28</time_frame>
    <description>Assessment of the maximum plasma concentration of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B Pharmacokinetics (Tmax)</measure>
    <time_frame>Day 1, 2, 7, 14 and 28</time_frame>
    <description>Assessment of the time to reach maximum observed plasma concentration of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B Pharmacokinetics (AUC)</measure>
    <time_frame>Day 1, 2, 7, 14 and 28</time_frame>
    <description>Assessment of the plasma area under the curve from time zero to 24 hours after dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B Pharmacokinetics (T1/2)</measure>
    <time_frame>Day 1, 2, 7, 14 and 28</time_frame>
    <description>Assessment of the plasma decay half life of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and B Pharmacokinetics (Ctrough)</measure>
    <time_frame>Day 1, 2, 7, 14 and 28</time_frame>
    <description>Assessment of the trough concentration of ONO-7579 in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A Overall Response Rate (ORR)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Assessed by investigator using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A Duration of Response (DoR)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Assessed by investigator using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A Progression Free Survival (PFS)</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Assessed by investigator using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Progression Free Survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessed by Independent Central Review using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Overall Survival (OS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessed by Independent Central Review using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Time to Response (TTR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessed by Independent Central Review using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Time to Progression (TTP)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Assessed by Independent Central Review using RECIST 1.1 or RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B Incidence, nature and severity of Adverse Events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Clinically significant changes in physical examinations</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Clinically significant changes in neurological examinations</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7579</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Clinically significant changes in vital signs and electrocardiogram - including the evaluation of the QT interval</measure>
    <time_frame>up to 24 months</time_frame>
    <description>To determine the safety and tolerability of ONO-7579</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>ONO-7579 Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Ascending doses of ONO-7579</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ONO-7579 Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Expansion phase of ONO-7579</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ONO-7579</intervention_name>
    <description>ONO-7579 Tablets</description>
    <arm_group_label>ONO-7579 Part A</arm_group_label>
    <arm_group_label>ONO-7579 Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Parts A and B):&#xD;
&#xD;
          1. Male or female aged at least 18 years or older, at the time of signing the informed&#xD;
             consent form.&#xD;
&#xD;
          2. The patient (or their legal representative) has provided written informed consent,&#xD;
             which signifies an agreement to enter the study and comply with the restrictions and&#xD;
             requirements listed in the informed consent form.&#xD;
&#xD;
          3. ECOG performance status ≤ 2&#xD;
&#xD;
          4. Life expectancy of at least 3 months&#xD;
&#xD;
          5. Patients must have measurable disease, according to RECIST 1.1 (defined as at least&#xD;
             one lesion that can be accurately measured in at least one dimension (longest diameter&#xD;
             to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm (≥2&#xD;
             cm) with conventional techniques or as ≥10 mm (≥1 cm) with spiral CT scan), or RANO&#xD;
             criteria for Glioma.&#xD;
&#xD;
          6. Patients must have received at least one prior line of therapy appropriate for their&#xD;
             tumor type and stage of disease. For glioma, patient must have received at least one&#xD;
             prior treatment with radiotherapy and temozolomide. Prior treatment of any Trk&#xD;
             inhibitor(s) is not an exclusion.&#xD;
&#xD;
          7. Adequate hematologic, hepatic and renal function as defined by the following criteria:&#xD;
&#xD;
               -  Absolute Neutrophil count ≥ 1.5x109&#xD;
&#xD;
               -  Platelet count ≥ 75,000 / mm3&#xD;
&#xD;
               -  Hemoglobin level ≥ 9.0 g/dL&#xD;
&#xD;
               -  Total Bilirubin level ≤ 1.5 X ULN&#xD;
&#xD;
               -  AST and ALT ≤ 3 X ULN&#xD;
&#xD;
               -  Creatinine clearance* ≥50 mL/min *estimated CLcr by the Cockcroft-Gault equation&#xD;
&#xD;
          8. Women of:&#xD;
&#xD;
               1. Childbearing potential must have a negative serum pregnancy test documented&#xD;
                  within 14 days prior to enrollment, and must agree to use two adequate methods of&#xD;
                  contraception from Day 1 of the study until 3 months after the end of treatment.&#xD;
                  Acceptable forms of effective contraception include;&#xD;
&#xD;
                    -  Established use of oral, injected or implanted hormonal methods of&#xD;
                       contraception.&#xD;
&#xD;
                    -  Placement of an intrauterine device or intrauterine system.&#xD;
&#xD;
                    -  Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/suppository.&#xD;
&#xD;
                    -  Male sterilization (with the appropriate post-vasectomy documentation of the&#xD;
                       absence of sperm in the ejaculate).&#xD;
&#xD;
               2. Non-childbearing potential, defined as females with a documented history of a&#xD;
                  clinically recognized procedure (e.g. hysterectomy, tubal ligation, bilateral&#xD;
                  salpingo-/oophorectomy) ; or postmenopausal defined as 12 months of spontaneous&#xD;
                  amenorrhea with follicle-stimulating hormone (FSH) &gt;40 MlU/mL). Females on&#xD;
                  hormone replacement therapy (HRT) will be required to use one of the&#xD;
                  contraception methods in Inclusion criteria 8a or must discontinue HRT to allow&#xD;
                  confirmation of post-menopausal status prior to being enrolled in the study.&#xD;
                  Following confirmation of their post-menopausal status, they can resume HRT&#xD;
                  during the study and will not be required to use contraception.&#xD;
&#xD;
          9. A male patient is eligible to participate if he is not trying to father a child and is&#xD;
             willing to use one of the relevant contraception methods as in inclusion criterion 8a&#xD;
             from Day 1 of the study until 3 months after the end of treatment.&#xD;
&#xD;
         10. Able to swallow tablets&#xD;
&#xD;
         11. Patients must be recovered to Grade 1 from the effects (excluding alopecia) of any&#xD;
             prior therapy for their malignancies.&#xD;
&#xD;
             Additional Criterion for Part A only&#xD;
&#xD;
         12. Patients with histologically/cytologically confirmed advanced solid tumors, and&#xD;
             documented tumor progression for whom no further standard anticancer treatment is&#xD;
             available.&#xD;
&#xD;
         13. Patients must be able to comply with the protocol requirements regarding fasting, as&#xD;
             determined by the investigator (excluding patients in food assessment cohort(s)).&#xD;
&#xD;
             Additional Criteria for Part B only&#xD;
&#xD;
         14. Patients with histologically/cytologically confirmed advanced solid tumors and&#xD;
             documented tumor progression for whom no further standard anticancer treatment exists&#xD;
             or where, in the opinion of the investigator, the existing standard anticancer&#xD;
             treatment options available are not expected to provide a reasonable benefit to the&#xD;
             patient.&#xD;
&#xD;
         15. Patients must have NTRK1, NTRK2 or NTRK3 gene fusion confirmed locally prior to first&#xD;
             dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Radiotherapy within two weeks prior to study entry&#xD;
&#xD;
          2. Major surgery (excluding placement of vascular access) within 4 weeks before the first&#xD;
             dose of study treatment&#xD;
&#xD;
          3. Spinal cord compression or brain metastases unless treated and radiologically stable&#xD;
             for &gt;6 weeks post treatment and not requiring steroids for at least 4 weeks prior to&#xD;
             start of study treatment&#xD;
&#xD;
          4. As judged by the Investigator, any evidence of severe or uncontrolled psychiatric&#xD;
             disease or systemic diseases, including history of suicide attempt or current suicidal&#xD;
             ideation or behavior, active infection including hepatitis B, hepatitis C and human&#xD;
             immunodeficiency virus (HIV). Screening for chronic conditions is not required.&#xD;
&#xD;
          5. Concurrent treatment with another investigational agent or participated in another&#xD;
             investigational trial within 30 days of study entry&#xD;
&#xD;
          6. Diagnosed or treated for a malignancy other than the tumor under investigation in the&#xD;
             study within 5 years, or who were previously diagnosed with a malignancy other than&#xD;
             that required for the study and have any radiographic or biochemical marker evidence&#xD;
             of that malignancy. Patients with completely resected basal cell carcinoma, squamous&#xD;
             cell carcinoma of the skin, or in situ malignancy are not excluded.&#xD;
&#xD;
          7. Clinically significant cardiovascular disease, including:&#xD;
&#xD;
               -  History of myocardial infarction, acute coronary syndromes (including unstable&#xD;
                  angina), or coronary angioplasty/stenting/bypass grafting within the past 6&#xD;
                  months.&#xD;
&#xD;
               -  History of Class III or IV heart failure as defined by the New York Heart&#xD;
                  Association (NYHA) functional classification system&#xD;
&#xD;
               -  Severe cardiac arrhythmia requiring medication or other severe conduction&#xD;
                  abnormalities (e.g. clinically significant QT prolongation or Torsade de pointes)&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Clinically significant valvular disease, cardiomegaly, ventricular hypertrophy,&#xD;
                  or cardiomyopathy&#xD;
&#xD;
          8. QT prolongation defined as a QTcF interval &gt;470 msec or other significant ECG&#xD;
             abnormalities including 2nd degree (type II) or 3rd degree AV block or bradycardia&#xD;
             (ventricular rate &lt;50 beats/min) on 12-lead ECG at screening&#xD;
&#xD;
          9. Serious concurrent medical conditions, including serious active infection, in the&#xD;
             opinion of the investigator&#xD;
&#xD;
         10. Female patients who are pregnant or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drug Development Division</last_name>
    <role>Study Director</role>
    <affiliation>Ono Pharmaceutical Co. Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>TRK</keyword>
  <keyword>TRKA</keyword>
  <keyword>TRKB</keyword>
  <keyword>TRKC</keyword>
  <keyword>NTRK1</keyword>
  <keyword>NTRK2</keyword>
  <keyword>NTRK3</keyword>
  <keyword>NTRK fusion positive</keyword>
  <keyword>NTRK1 fusion</keyword>
  <keyword>NTRK2 fusion</keyword>
  <keyword>NTRK3 fusion</keyword>
  <keyword>NTRK1 gene rearrangement</keyword>
  <keyword>NTRK2 gene rearrangement</keyword>
  <keyword>NTRK3 gene fusion</keyword>
  <keyword>ETV6-NTRK3</keyword>
  <keyword>fusion</keyword>
  <keyword>tumors</keyword>
  <keyword>solid tumors</keyword>
  <keyword>CNS tumors</keyword>
  <keyword>central nervous system tumors</keyword>
  <keyword>TRK fusion</keyword>
  <keyword>ETV6</keyword>
  <keyword>ETV6 fusion</keyword>
  <keyword>solid CNS tumor</keyword>
  <keyword>advanced CNS tumor</keyword>
  <keyword>primary CNS tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>ONO-7579</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

